Med tech company executives often talk about the need to provide not just products but "solutions" to problems like meeting Affordable Care Act metrics at hospitals and lowering the cost of patient care. Now, Medtronic is expanding its push into healthcare services to a new front with the acquisition of the Netherlands' diabetes and research clinic Diabeter.
Biopharma has been on a bona fide dealmaking binge. Trouble is, that binge is starting to get too expensive--and too risky. That's what Fitch Ratings says in a new report that cautions against fast-and-loose dealmaking.
Boston Scientific added to an existing strength in endoscopy by acquiring Xlumena for up to $75 million plus undisclosed sales milestones.
Indian conglomerate Piramal has sold off its CRO business to Indoco Remedies, getting rid of a business "not considered strategic in nature," according to the company.
Orthofix has secured an 18-month option to buy eNeura with a $15 million loan. The financing is designed to support the commercialization of the startup's Spring TMS device that FDA cleared last May and is the first portable device available in the U.S. to treat acute pain associated with migraine headache with aura, according to the company.
Actavis' agreement to buy Allergan for $66 billion put then-Allergan CEO David Pyott in line for a hefty payout in cash and shares--and now that the tie-up is official, he's collecting.
CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.
Thanks to deals signed on Monday alone, another $17 billion is set to change hands in the hyperacquisitive drug business, a single-day record that closes out a bracing quarter for buyouts. But with industry titans paying ever-higher prices for a shrinking number of assets, how long can the good times roll?
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
Abbott Laboratories is selling off one-third of the stake in Mylan it acquired through last year's stock swap, a few weeks after Mylan wrapped up its $5.3 billion buyout of Abbott's portfolio of specialty and branded drugs.